A Phase 2 proof-of-mechanism trial in early-stage Alzheimer disease with surrogate inflammatory and cognitive endpoints; results not yet reported in this registry record.
Reported
Planned sample size55
Study phasePhase 2
Primary outcome: cognitive endpoi…ADAS-Cog 13 score change from baseline to W…